Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more
Eris Lifesciences Limited (ERIS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.068x
Based on the latest financial reports, Eris Lifesciences Limited (ERIS) has a cash flow conversion efficiency ratio of 0.068x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹2.39 Billion) by net assets (₹35.03 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eris Lifesciences Limited - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Eris Lifesciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Eris Lifesciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eris Lifesciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Genertec Universal Medical Group Company Limited
F:5UM
|
-0.073x |
|
Vestjysk Bank A/S
CO:VJBA
|
0.003x |
|
United International Enterprises Ltd.
LSE:0KGQ
|
N/A |
|
Qingdao Haier Biomedical Co Ltd
SHG:688139
|
0.002x |
|
Nine Dragons Paper (Holdings) Limited
PINK:NDGPF
|
0.086x |
|
Angang Steel Company Limited
PINK:ANGGF
|
0.034x |
|
CTT - Correios De Portugal S.A
PINK:CTTOF
|
-0.037x |
|
Century Iron And Steel Industrial Co Ltd
TW:9958
|
0.057x |
Annual Cash Flow Conversion Efficiency for Eris Lifesciences Limited (2012–2025)
The table below shows the annual cash flow conversion efficiency of Eris Lifesciences Limited from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹32.72 Billion | ₹10.65 Billion | 0.326x | +115.80% |
| 2024-03-31 | ₹32.22 Billion | ₹4.86 Billion | 0.151x | +14.82% |
| 2023-03-31 | ₹22.21 Billion | ₹2.92 Billion | 0.131x | -33.73% |
| 2022-03-31 | ₹19.08 Billion | ₹3.78 Billion | 0.198x | -16.75% |
| 2021-03-31 | ₹15.76 Billion | ₹3.75 Billion | 0.238x | +13.85% |
| 2020-03-31 | ₹12.96 Billion | ₹2.71 Billion | 0.209x | +9.62% |
| 2019-03-31 | ₹11.69 Billion | ₹2.23 Billion | 0.191x | -27.96% |
| 2018-03-31 | ₹8.86 Billion | ₹2.35 Billion | 0.265x | -28.46% |
| 2017-03-31 | ₹5.40 Billion | ₹2.00 Billion | 0.370x | -8.77% |
| 2016-03-31 | ₹3.24 Billion | ₹1.31 Billion | 0.406x | +21.46% |
| 2015-03-31 | ₹2.70 Billion | ₹900.57 Million | 0.334x | -32.59% |
| 2014-03-31 | ₹1.81 Billion | ₹896.24 Million | 0.496x | +44.48% |
| 2013-03-31 | ₹1.11 Billion | ₹380.15 Million | 0.343x | -40.12% |
| 2012-03-31 | ₹528.98 Million | ₹302.99 Million | 0.573x | -- |